RXi Pharmaceuticals announced ‘positive’ results with RXI-109 in a Phase 1/2 clinical trial. RXI-109-1501 is a study evaluating the safety and tolerability of RXI-109 injections in the eye of subjects with advanced neovascular age-related macular degeneration, and accompanying subretinal fibrosis. During this study, the clinical effect of these injections was evaluated as a secondary endpoint. The primary objective was met as shown by the absence of dose-limiting and serious toxicities, and study results show that RXI-109 was safe and well tolerated for all patients included in the three dosage groups. Several assessments were included to measure a potential clinical effect. There were no instances of Dose Limiting Toxicities or Serious Toxicities throughout the study. Compared to the baseline visit, all but one subject had an improved best corrected visual acuity of the study eye at the last follow up visit.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.